GELS

Gelteq Limited Ordinary Shares

GELS

Market cap $14.2M

Overview Fund Activity

1.42 USD

-0.18

11.25%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

1.47

+0.05

3.52%

1 day

-11.25%

5 days

-7.79%

1 month

6.77%

3 months

-25.65%

6 months

16.39%

Year to date

-40.34%

1 year

-51.7%

5 years

-51.7%

10 years

-51.7%

About: Gelteq Ltd is a clinical and science-based company that is focused on developing and commercializing white-label gel-based delivery solutions to preserve the simplicity, accessibility and efficacy of oral delivery without the impediments traditionally associated with other oral delivery methods, with prescription drugs, nutraceuticals, pet care, and other products. It is engaged in the development and testing of a gel-based delivery system for humans and pets. Its principal products are edible gels.

Employees: 8

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

70% more capital invested

Capital invested by funds: $108K [Q1] → $183K (+$75.4K) [Q2]

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

20% more funds holding

Funds holding: 5 [Q1] → 6 (+1) [Q2]

0.01% more ownership

Funds ownership: 1.11% [Q1] → 1.12% (+0.01%) [Q2]

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

See Fund Rankings

Financial journalist opinion

Based on 3 articles about GELS published over the past 30 days

Gelteq Technology Powers U.S. Product Launches of its Nutraceutical Products for Partner

MELBOURNE, Australia, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company,” NASDAQ: GELS), a clinical and science-based developer of gel-based oral delivery solutions, welcomes the recently announced product launches of Healthy Extracts, Inc. (“Healthy Extracts,” OTCQB: HYEX), whose products apply Gelteq's proprietary gel technology, into the U.S. nutraceutical market.

Gelteq Technology Powers U.S. Product Launches of its Nutraceutical Products for Partner

Gelteq Announces Commencement of Preclinical Trial for Novel Gel-Based Antihistamine Formulation Targeting Allergy Market

MELBOURNE, Australia, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced plans to commence a preclinical bioequivalence study in September 2025 to evaluate its novel gel-based formulation of a widely used antihistamine for allergy treatment.

Gelteq Announces Commencement of Preclinical Trial for Novel Gel-Based Antihistamine Formulation Targeting Allergy Market

Healthy Extracts Builds Upon Record Q2 Results and Transformative Merger with Launch of New Revolutionary Hydration and Sugar Metabolism Gel-Packs

Hydrate EZ™ delivers rapid hydration and essential electrolytes for staying refreshed, sharp and in control. Mynus Sugar™ is clinically formulated to support healthy carbohydrate metabolism.

Healthy Extracts Builds Upon Record Q2 Results and Transformative Merger with Launch of New Revolutionary Hydration and Sugar Metabolism Gel-Packs

Healthy Extracts Reports Record Q2 2025 Net Revenue, Driving Positive EPS and EBITDA; Increases 2025 Net Revenue Guidance by 50%

Net Revenue Outlook for 2025 Increased from $4.2 Million+ to $6.3 Million+, Representing Growth of 102%+, Based on Recent Transformative Merger with Gummy USA LAS VEGAS, NV / ACCESS Newswire / August 13, 2025 / Healthy Extracts Inc. (OTCQB:HYEX), a leader in plant-based nutraceutical innovations, reported results for its second quarter and six months ended June 30, 2025. All comparisons are to the same year-ago period unless otherwise noted.

Healthy Extracts Reports Record Q2 2025 Net Revenue, Driving Positive EPS and EBITDA; Increases 2025 Net Revenue Guidance by 50%

Healthy Extracts Expects Record Sales for Q2 2025, Driving Strong Positive Adj. EBITDA

Q2 2025 adjusted EBIDTA at nearly $100,000, demonstrating strong leverage in the company's marketing and distribution channel platform. Subscription-based recurring revenue continues to drive strong positive cash flow with more than 107% increase from Amazon "Subscribe & Save" customers and 88% increase in DTC subscription customers.

Healthy Extracts Expects Record Sales for Q2 2025, Driving Strong Positive Adj. EBITDA

Gelteq Announces Agreement with IDT Australia to Secure Dedicated New Product Development and Manufacturing Facilities

Partnership to support the scale-up and commercialization of Gelteq's proprietary gel-based oral delivery platform Partnership to support the scale-up and commercialization of Gelteq's proprietary gel-based oral delivery platform

Gelteq Announces Agreement with IDT Australia to Secure Dedicated New Product Development and Manufacturing Facilities

Gelteq Expands U.S. Operations with Healthy Extracts Inc. as North American Fulfillment Partner

Major commercial expansion of its U.S. strategy through logistics and distribution agreement Major commercial expansion of its U.S. strategy through logistics and distribution agreement

Gelteq Expands U.S. Operations with Healthy Extracts Inc. as North American Fulfillment Partner

Gelteq's Sportsgel Brand Named Official Sponsor of the Professional Pickleball Tour and League of Australia and New Zealand

Sportsgel signs first league-wide sports deal to be the official performance gel of the preeminent pickleball tour across the Oceania region Sportsgel signs first league-wide sports deal to be the official performance gel of the preeminent pickleball tour across the Oceania region

Gelteq Appoints Matthew Jones as Head of Sports Performance

Leading internationally-experienced sports nutritionist joins the Company's growing team to expand its sports vertical Leading internationally-experienced sports nutritionist joins the Company's growing team to expand its sports vertical

Gelteq Appoints Matthew Jones as Head of Sports Performance

Gelteq Receives FDA Approval of its Suitability Petition for New Animal Drug

Approval grants Gelteq fast track pathway for drug and entrance into the animal pharmaceuticals space Approval grants Gelteq fast track pathway for drug and entrance into the animal pharmaceuticals space

Gelteq Receives FDA Approval of its Suitability Petition for New Animal Drug

See News Rankings

Charts implemented using Lightweight Charts™